Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo and Opdivo Qvantig
nivolumab (IV or with hyaluronidase-nvhy SC) · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Limits nivolumab with fluoropyrimidine and platinum chemotherapy to adults with advanced or metastatic gastric cancer, GEJ cancer, or esophageal adenocarcinoma whose tumors express PD-L1 at least 1.
LAMPGEN ANALYSIS
Why it matters
The revised eligibility criteria apply to the chemotherapy combination with either nivolumab formulation in this gastroesophageal adenocarcinoma setting.
What research teams should watch
Update patient selection templates for the PD-L1 threshold and ensure the route-specific administration order matches the intended regimen.
PRIMARY RECORDS